Why the study?
Does intravenous iron supplementation improve functional capacity and clinical outcomes in patients with heart failure and iron deficiency?
Does intravenous iron supplementation improve functional capacity and clinical outcomes in patients with heart failure and iron deficiency?
Intravenous ferric carboxymaltose is an effective therapy for iron deficiency in heart failure, improving symptoms and reducing hospitalizations, whereas oral iron is ineffective.
No takes yet. Share an insight, caveat, or question.
IV iron may reduce HF hospitalizations in iron-deficient patients; extends trial evidence but should not yet alter broad practice without further RCTs.
Rizzo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: